UBS Maintains Buy on Adient, Lowers Price Target to $22
UBS analyst Joseph Spak maintains Adient (NYSE:ADNT) with a Buy and lowers the price target from $23 to $22.
Share
Why It Matters
A big bank analyst still likes Adient but thinks it is worth slightly less money. This shows the company is still doing okay, but maybe not growing as fast as before.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.